1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions

Healthy

Interventions

DRUG

OPT101

15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40

Trial Locations (1)

IMMUNOe Research, Centennial

All Listed Sponsors

lead

Op-T LLC

INDUSTRY

NCT04589403 - 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide. | Biotech Hunter | Biotech Hunter